
August 9, 2014	Web Version \| Share with a colleague \| eNews Subscribe	You are subscribed to the FormularyWatch eNews

FDA approves oritavancin for skin infections

FDA has approved oritavancin (Orbactiv, The Medicines Company) for injection for treating adults with acute bacterial skin and skin structure infections caused by susceptible designated Gram-positive bacteria, including MRSA.
» Can this drug improve patient compliance?

Drug Overview: Tasimelteon (Hetlioz)

The FDA approval of Hetlioz has significant implications on the treatment of N24HSWS in blind patients since there has been no other drug that has been indicated in this particular population. » For more on Hetlioz

#icymi